UK Govt announces £13.6 million taxpayer money for US pro-abortion lobby group

In a recent debate in the House of Lords on global gender equality, Baroness Sugg revealed that the Department for International Development (DfID) had increased its funding for the American pro-abortion think tank, the Guttmacher Institute.

On returning from the Women Deliver conference in Vancouver, Baroness Sugg “was also pleased to announce an uplift to [DfID’s] programme with the Guttmacher Institute, bringing our current support to £13.6 million.”

It transpires that DfiD have been working with the pro-abortion think tank in their promotion of sexual and reproductive health and rights, which includes promoting access to abortion.

Historically, the Guttmacher Institute was a part of America’s largest abortion provider, Planned Parenthood, and continues to have close ties with that organisation.

In 2015, Planned Parenthood were embroiled in a scandal after they were discovered to negotiating the trading of baby body parts for research. Planned Parenthood abortionists were filmed altering how they conducted abortions in order to best harvest the desired organ(s) of the unborn baby.

DfID support for this the Guttmacher Institute is in addition to funding that has previously been provided to other abortion lobby groups. This year DfID gave IPPF £132 million in funding for a two-year programme, despite the ongoing sexual scandals within the company.

Furthermore, in April, Penny Modaunt MP, as International Development Secretary, pledged an additional £42 million to IPPF (alongside Marie Stopes International) to look at the “neglected issue” of safe abortion in developing countries.

Clare McCarthy of Right To Life UK said: “ DfID’s use of taxpayer’s money to fund the pro-abortion research group, Guttmacher Institute, as well as the scandal ridden IPPF is disgraceful.”

“There is no popular support for this international abortion advocacy as 65% of people in Britain oppose the use of taxpayer money being used to fund overseas abortions.”

US stops federal funding for research using aborted baby parts

Adobe Stock/Photographee.eu

The US Department of Health and Social Services (HHS) has ended taxpayer funded federal research using the remains of aborted foetuses.

HHS recognised “the dignity of human life” as a “top priority” in determining what counts as ethical research. “Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump’s administration,” the department said in a statement.”

However, privately funded research using parts of aborted babies is still able to continue.

Any research from the National Institutes of Health (NIH) that desires to use new foetal remains for its research will no longer be conducted under this policy change.

As for future aborted-tissue research that applies for federal funding but takes place outside NIH, “an ethics advisory board will be convened to review the research proposal and recommend whether, in light of the ethical considerations, NIH should fund the research project—pursuant to a law passed by Congress.”

HHS also said that it was committed to funding ethical alternatives which does not involve the use of foetal remains.

After an abortion, it is possible to harvest the dead foetal remains for use in medical research.

Planned Parenthood were embroiled in a scandal in 2015 after they were discovered to negotiating the trading of baby body parts for research. The British Pregnancy Advisory Service (BPAS) also openly admitted to being involved in harvesting of baby parts for research following an abortion.

However, biochemistry expert Dr. Tara Sander Lee testified before the US Congress last December that fetal tissue research is medically unnecessary.

She explained that “after over 100 years of research, no therapies have been discovered or developed that require aborted fetal tissue,” and that researchers have access to a wealth of ethical sources for human tissue, including cells that can be given the coveted quality of pluripotency, or the ability to become other types of tissue.